data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzdoNTEydjM0MS4zMjZIMHoiLz48cGF0aCBmaWxsPSIjRkY5ODExIiBkPSJNMCA4NS4zMzdoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjNkRBNTQ0IiBkPSJNMCAzMTIuODg4aDUxMnYxMTMuNzc1SDB6Ii8+PGNpcmNsZSBmaWxsPSIjMDA1MkI0IiBjeD0iMjU2IiBjeT0iMjU2IiByPSI0My44OTYiLz48Y2lyY2xlIGZpbGw9IiNGRkYiIGN4PSIyNTYiIGN5PSIyNTYiIHI9IjI3LjQzNCIvPjxwYXRoIGZpbGw9IiMwMDUyQjQiIGQ9Ik0yNTYgMjIyLjE0Nmw4LjQ2NCAxOS4xOTUgMjAuODU1LTIuMjY4TDI3Mi45MjcgMjU2bDEyLjM5MiAxNi45MjctMjAuODU1LTIuMjY4TDI1NiAyODkuODU0bC04LjQ2NC0xOS4xOTUtMjAuODU1IDIuMjY4TDIzOS4wNzMgMjU2bC0xMi4zOTItMTYuOTI3IDIwLjg1NSAyLjI2OHoiLz48L3N2Zz4=

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Cocrystal Pharma

(NASDAQ:COCP)

Intraday

$1.48

-0.082[-5.25%]

After-Hours

$1.48

0[0.00%]

Perks Buy Compare Brokers

$1.48

-0.082[-5.25%]

At close: Apr 15

$1.48

0[0.00%]

PreMarket: 9:23AM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma Stock (NASDAQ: COCP)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 10, 2024

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Apr 10, 2024, 8:09AM

Thursday, April 04, 2024

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
Benzinga Newsdesk - Apr 4, 2024, 6:24AM

Thursday, March 28, 2024

Cocrystal Pharma Q4 EPS $(0.44) Beats $(0.60) Estimate
Benzinga Newsdesk - Mar 28, 2024, 11:14AM
Recap: Cocrystal Pharma Q4 Earnings
Benzinga Insights - Mar 28, 2024, 9:50AM

Wednesday, March 20, 2024

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $10 Price Target
Benzinga Newsdesk - Mar 20, 2024, 6:47AM

Tuesday, March 19, 2024

Cocrystal Pharma Receives Pre-IND Responses From The FDA On Oral CC-42344 For Treating Influenza A
Benzinga Newsdesk - Mar 19, 2024, 8:02AM

Thursday, January 04, 2024

Cocrystal Pharma Provides An Update On The Clinical Development Of Its Novel, Broad-Spectrum Antiviral Investigational Candidates
Benzinga Newsdesk - Jan 4, 2024, 8:13AM

Wednesday, January 03, 2024

HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $10
Benzinga Newsdesk - Jan 3, 2024, 8:43AM

Thursday, December 21, 2023

Cocrystal Pharma Received Notice From Merck On December 15, 2023, Terminating Their Collaboration Agreement From January 2, 2019, Effective March 14, 2024, Ending Their Joint Development Of Influenza A/B Antiviral Compounds
Charles Gross - Dec 21, 2023, 5:05PM

Wednesday, December 06, 2023

Cocrystal Pharma Announces First-Patient-In For Phase 2a Human Challenge Study Evaluating Oral CC-42344 In Pandemic And Seasonal Influenza A
Benzinga Newsdesk - Dec 6, 2023, 8:06AM

Monday, December 04, 2023

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Benzinga Newsdesk - Dec 4, 2023, 6:59AM

Wednesday, November 29, 2023

Cocrystal Pharma Announces The Presentation Of Data Demonstrating The Activity Of Its Potent Broad-spectrum PB2 Inhibitor CC-42344 Against Pandemic And Seasonal Influenza A Strains At The World Vaccine Congress West Coast
Benzinga Newsdesk - Nov 29, 2023, 8:14AM

Thursday, November 16, 2023

12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights - Nov 16, 2023, 4:31PM

Wednesday, November 15, 2023

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Nov 15, 2023, 4:31PM

Monday, November 13, 2023

Recap: Cocrystal Pharma Q3 Earnings
Benzinga Insights - Nov 13, 2023, 8:35AM
Cocrystal Pharma Q3 EPS $(0.41) Beats $(0.53) Estimate
Benzinga Newsdesk - Nov 13, 2023, 8:14AM

Tuesday, October 31, 2023

Cocrystal Pharma Receives UK MHRA Authorization To Initiate Its Phase 2a Influenza Human Challenge Trial With Oral PB2 Inhibitor CC-42344
Benzinga Newsdesk - Oct 31, 2023, 8:04AM

Wednesday, October 04, 2023

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Benzinga Newsdesk - Oct 4, 2023, 6:18AM

Thursday, September 28, 2023

Cocrystal Pharma Doses First Subjects In Phase 1 Study of CDI-988 For Pandemic Norovirus and Coronavirus
Benzinga Newsdesk - Sep 28, 2023, 8:07AM

Tuesday, August 15, 2023

Analyst Ratings for Cocrystal Pharma
Benzinga Insights - Aug 15, 2023, 3:00PM
HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Benzinga Newsdesk - Aug 15, 2023, 6:55AM

Monday, August 14, 2023

Cocrystal Pharma Q2 EPS $(0.50) Beats $(0.58) Estimate
Happy Mohamed - Aug 14, 2023, 8:46AM

Friday, August 11, 2023

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Benzinga Newsdesk - Aug 11, 2023, 7:09AM

Tuesday, August 08, 2023

Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 As Norovirus Lead
Happy Mohamed - Aug 8, 2023, 8:19AM

Friday, July 21, 2023

Board Member at Cocrystal Pharma Acquires Company Stock Options Worth 24,417 Shares
Benzinga Insights - Jul 21, 2023, 11:01AM
Cocrystal Pharma Board Member Awarded $36K Worth of Stock Options
Benzinga Insights - Jul 21, 2023, 11:01AM
Cocrystal Pharma Board Member Awarded $52K Worth of Stock Options
Benzinga Insights - Jul 21, 2023, 11:00AM
Cocrystal Pharma Board Member Awarded $46K Worth of Stock Options
Benzinga Insights - Jul 21, 2023, 11:00AM
Director at Cocrystal Pharma Acquires Company Stock Options Worth 7,333 Shares
Benzinga Insights - Jul 21, 2023, 11:00AM

Thursday, June 15, 2023

Cocrystral Pharma May Offer, Sell Shares Of Common Stock Of Up To $7.25M From Time To Time
Benzinga Newsdesk - Jun 15, 2023, 5:00PM

Friday, June 02, 2023

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Benzinga Newsdesk - Jun 2, 2023, 6:36AM
HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $12 Price Target
Benzinga Newsdesk - Jun 2, 2023, 6:36AM

Wednesday, May 31, 2023

Cocrystal Pharma Receives HREC Approval To Initiate Phase 1 Study To Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
Benzinga Newsdesk - May 31, 2023, 8:03AM

Wednesday, May 24, 2023

HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $12
Benzinga Newsdesk - May 24, 2023, 6:36AM

Monday, May 15, 2023

Cocrystal Pharma Q1 EPS $(0.64) Misses $(0.59) Estimate
Benzinga Newsdesk - May 15, 2023, 8:09AM

Thursday, May 04, 2023

Cocrystal Pharma Presents New Data From Its CC-42344 Phase 1 Influenza A Study At The 7th Annual ISIRV Antiviral Group Conference
Happy Mohamed - May 4, 2023, 5:05PM

Tuesday, May 02, 2023

Cocrystal Pharma Receives Notice Of Allowance For U.S. Patent Titled 'COMBINATION THERAPY FOR TREATMENT OF HEPATITIS C VIRUS'
Benzinga Newsdesk - May 2, 2023, 3:34PM

Tuesday, April 18, 2023

Cocrystal Pharma To Present New Data From Its CC-42344 Phase 1 Influenza A Study At The 7th Annual ISIRV Antiviral Group Conference
Happy Mohamed - Apr 18, 2023, 8:38AM

Wednesday, April 12, 2023

Fred Hassan Reports Passive Stake Of 10% In Cocrystal Pharma Inc As Of April 4, 2023
Steve Krause - Apr 12, 2023, 4:29PM

Monday, April 10, 2023

Why Cocrystal Pharma Shares Are Trading Higher Today
Sean Torres - Apr 10, 2023, 2:43PM
Cocrystal Pharma shares are trading higher after the company completed a $4 million private placement.
Benzinga Newsdesk - Apr 10, 2023, 1:40PM
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Apr 10, 2023, 12:42PM
$2M Bet On Cocrystal Pharma? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin - Apr 10, 2023, 9:05AM
Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Apr 10, 2023, 8:26AM

Friday, April 07, 2023

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Apr 7, 2023, 5:31PM

Friday, March 31, 2023

Cocrystal Pharma Shares See Volume; Zack's Small Cap Research Sets $7 Valuation
Benzinga Newsdesk - Mar 31, 2023, 2:03PM

Wednesday, March 29, 2023

Cocrystal Pharma FY EPS $(4.77) Misses $(4.10) Estimate
Benzinga Newsdesk - Mar 29, 2023, 8:08AM

Wednesday, January 25, 2023

Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jan 25, 2023, 7:48AM

Tuesday, January 24, 2023

HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $35
Benzinga Newsdesk - Jan 24, 2023, 6:09AM

Monday, January 23, 2023

Cocrystal Pharma Discusses Clinical Progress And Significance Of Its Novel Antiviral Therapeutics Pipeline With The Stock Day Podcast
Benzinga Newsdesk - Jan 23, 2023, 9:21AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved